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The fungal meningitis pathogen Cryptococcus neo-
formans is a central driver of mortality in HIV/AIDS.
We report a genome-scale chemical genetic data
map for this pathogen that quantifies the impact of
439 small-molecule challenges on 1,448 gene knock-
outs. We identified chemical phenotypes for 83% of
mutants screened and at least one genetic response
for each compound.C. neoformans chemical-genetic
responses are largely distinct from orthologous pub-
lished profiles of Saccharomyces cerevisiae, demon-
strating the importance of pathogen-centered
studies. We used the chemical-genetic matrix to pre-
dict novel pathogenicity genes, infer compound
mode of action, and to develop an algorithm, O2M,
that predicts antifungal synergies. These predictions
were experimentally validated, thereby identifying
virulence genes, a molecule that triggers G2/M arrest
and inhibits the Cdc25 phosphatase, and many com-
pounds that synergize with the antifungal drug flu-
conazole. Our work establishes a chemical-genetic
foundation for approaching an infection responsible
for greater than one-third of AIDS-related deaths.
INTRODUCTION
Invasive fungal infections are notoriously difficult to diagnose
and treat, resulting in high mortality rates, even with state-of-
the art treatments. The three most common pathogenic agents
are Cryptococcus neoformans, Candida albicans, and Asper-
gillus fumigatus (Mandell et al., 2010). These organisms are
opportunistic fungi that prey on individuals with varying degrees
of immune deficiency. Susceptible patient populations include
premature infants, diabetics, individuals with liver disease,
chemotherapy patients, organ transplant recipients, and those1168 Cell 159, 1168–1187, November 20, 2014 ª2014 Elsevier Inc.infectedwith HIV (Mandell et al., 2010). Compounding the clinical
challenge is the slow pace of antifungal drug development: only
a single new class of drugs (the echinocandins) has been
approved for use in the United States in the last 30 years (Butts
and Krysan, 2012; Mandell et al., 2010; Roemer et al., 2011).
Fungal infections are estimated to cause 50% of deaths
related to AIDS and have been termed a ‘‘neglected epidemic’’
(Armstrong-James et al., 2014). The fungus chiefly responsible
for deaths in this population isC. neoformans (Armstrong-James
et al., 2014).C. neoformans is an encapsulated basidiomycetous
haploid yeast distantly related to Saccharomyces cerevisiae and
Schizosaccharomyces pombe. A 2009 CDC study estimated
that 1 million infections and 600,000 deaths annually are
caused by C. neoformans, exceeding the estimated worldwide
death toll from breast cancer (Lozano et al., 2012; Park et al.,
2009). C. neoformans is widespread in the environment and
exposure occurs through inhalation of desiccated yeast or
spores (Heitman et al., 2011). In immunocompromised patients,
C. neoformans replicates and disseminates, causing meningo-
encephalitis that is lethal without treatment (Heitman et al.,
2011). Induction therapy involves flucytosine and intravenous in-
fusions of amphtotericin B (Loyse et al., 2013). Both drugs are
highly toxic, difficult to administer, and neither is readily available
in the areas with the highest rates of disease. The current recom-
mendation for Cryptococcosis treatment is at least a year of ther-
apy, which is difficult to accomplish in resource-limited settings
(WHO, 2011). Thus, as is the case with infections caused by
other fungal pathogens, effective treatment of cryptococcal in-
fections is limited by the efficacy, toxicity, and availability of cur-
rent pharmaceuticals.
We implemented chemogenomic profiling to approach the
challenges of therapeutic development in C. neoformans. This
method involves the systematic measurement of the impact of
compounds on the growth of defined null mutants to produce
a chemical-genetic map. Such a map represents a quantitative
description composed of numerical scores indicative of the
growth behavior of each knockout mutant under each chemical
condition. Cluster analysis of the growth scores for large
numbers of mutants under many chemical conditions can reveal
genes that function in the same pathway and even those whose
products are part of the same protein complex (Collins et al.,
2007; Parsons et al., 2004; Parsons et al., 2006). In addition,
the identity of genes whose mutation produce resistance or
sensitivity is useful for uncovering compound mode of action
(MOA) (Hillenmeyer et al., 2008; Jiang et al., 2008; Nichols
et al., 2011; Parsons et al., 2006; Xu et al., 2007; Xu et al.,
2009). Large-scale studies have been restricted to model organ-
isms for which gene deletion collections have been constructed,
namely S. cerevisiae, S. pombe, and Escherichia coli K12 (Hillen-
meyer et al., 2008; Nichols et al., 2011; Parsons et al., 2006).
However, as none of these are pathogens, the extent to which
the resulting insights translate to pathogenic organisms is un-
known. A variation on chemogenomic profiling, chemically-
induced haploinsufficiency, was first developed using a diploid
heterozygote gene deletion library S. cerevisiae to identify com-
pound MOA. This method, which identifies genes that impact
compound sensitivity based on a two-fold gene dosage change,
is suited for diploid organisms and has been used in the path-
ogen C. albicans (Jiang et al., 2008; Xu et al., 2007; Xu et al.,
2009).
We report here the generation of a large-scale chemogenomic
map for C. neoformans using defined, commonly available
knockout mutants, assessments of data quality, and extensive
experimental verification. Comparisons of the C. neoformans
profile with two large-scale published profiles from
S. cerevisiae revealed that for most types of compounds, the
chemical-genetic interactions are distinct even among ortholo-
gous genes, emphasizing the importance of pathogen-focused
investigation. We used nearest-neighbor analysis to predict
new genes involved in polysaccharide capsule formation and
infectivity, which we validated through experiment. We also uti-
lized genetic responses to predict the G2/M phase of the cell
cycle and the Cdc25 phosphatase as targets of a thiazolidone-
2,4-dione derivative, which we confirmed in vivo and in vitro.
Finally, because of the unmet need for improved antifungal
drug efficacy, we developed a new algorithm, O2M, to predict
new compound synergies based on the profiles of pairs known
to be synergistic. Experimental tests demonstrate that the
method performs vastly better than randomexpectation, thereby
enabling the identification of synergistic compound combina-
tions. Our studies establish a chemical-genetic foundation to
approach the biology and treatments of C. neoformans infec-
tions, which are responsible for more than one-third of HIV/
AIDS deaths worldwide.
RESULTS
A Chemical-Genetic Map of C. neoformans
We assembled 1,448 C. neoformans gene deletion strains (Chun
et al., 2011; Liu et al., 2008) (Table S1 available online), corre-
sponding to a substantial fraction of 6,967 predicted
C. neoformans genes (Janbon et al., 2014), and a collection of
compounds for screening (Table 1). Compounds were selected
based on cost and literature evidence that they could inhibit
the growth of fungi. Where feasible, compounds were chosen
that are known to target specific biological processes. ForCeach small molecule, we determined an approximate minimum
inhibitory concentration (MIC) in agar, then measured growth
of the knockout collection on each small molecule at 50%,
25%, and 12.5%MIC using high density agar plate colony arrays
and a robotic replicator. We then measured the size of each col-
ony using flatbed scanning and colony measurement software
(Dittmar et al., 2010). We performed a minimum of four replicate
colony measurements for each mutant-condition pair. Plate-
based assays are subject to known nonbiological effects, such
as spatial patterns. To mitigate these errors, a series of correc-
tive measures were implemented using approaches described
previously, including manual filtration of noisy data, spatial effect
normalization and machine learning-based batch correction
(Baryshnikova et al., 2010). In addition, the data for each deletion
mutant and compound was centered and normalized. Each
mutant-small molecule combination was assigned a score with
positive scores representing relative resistance and negative
scores representing compound sensitivity (Table S2). A global
summary of the processed data organized by hierarchical clus-
tering is shown in Figure 1A.
The importance and validity of the computational corrections
is shown in Figures 1B and S1. We estimated how reproducible
the chemical-genetic profiles were by calculating the correlation
scores for data obtained for different concentrations of the same
small molecule (purple). This measures the degree of overlap
between the overall chemical-genetic profiles, which are them-
selves each composed of a score for each mutant-small mole-
cule combination. We found significant correlation (p = 2.67 3
10176) between data obtained for different concentrations of
the same small molecule compared to those between profiles
generated by data set randomization, suggesting significant
reproducibility. Moreover, correlation scores between chemi-
cal-genetic profiles of different concentrations of different com-
pounds (gray) are centered at approximately 0 (Figure 1B). This
difference in correlation scores is apparent even when
comparing experiments performed on the same day, when
spurious batch signal can contribute to false positives (Baryshni-
kova et al., 2010). Our batch-correction algorithms resulted in
same-batch screening data with strong positive correlation
scores for the same compounds but correlation scores close
to zero for different compounds (Figure S1), demonstrating suc-
cessful removal of spurious signal (Baryshnikova et al., 2010).
We compared chemical-genetic profiles between compounds
in the azole family (Figure 1C). Despite the fact that the azoles
tested include those of diverse uses, from agricultural pesticides
to FDA-approved drugs (Table 1), many exhibit a significant pro-
file correlation (p = 2.82 3 106), further indicating significant
signal in the data. As a final assessment, we performed hyper-
geometric testing across all compounds to determine whether
the same sensitive gene knockouts (defined by Z < 2.5) are
identified at different concentrations of the same compounds.
Using a Bonferonni-corrected p value cutoff, nearly all com-
pounds display significant overlap of responsive genes at
different concentrations (Figure 1D).
We assigned at least one phenotype (sensitivity or resistance
to a compound) to 1,198 of 1,448 mutants (Figure 1E, Tables S2,
S3, and S4). Of these, 855 exhibit one to ten phenotypes, while
remaining 343 displayed from 11 to 146 phenotypes. Geneell 159, 1168–1187, November 20, 2014 ª2014 Elsevier Inc. 1169
Table 1. Small Molecules and Targets
Inhibitor (Activator)
Highest
Screening Conc. Process/Enzyme Category Pubchem ID FDA Approval?
1-10 phenanthroline
hydrochloride
monohydrate
2 uM broad/transition metal
complexes
broad spectrum 2723715 no
2-aminobenzothiazole 30 uM cytoskeleton function/
kinesin Kip1
cell structure 8706 no
2-hydroxyethylhydrazine 0.156% lipid synthesis/phospholipid
methylation
lipid biosynthesis 8017 no
3-aminotriazole 6.25 mM histidine synthesis/IMP
dehydratase
metabolism 1639 no
4-hydroxytamoxifen 1.56 uM estrogen receptor (mammals) signaling 449459 yes
5-fluorocytosine 2.5 ug/ml DNA/RNA biosynthesis DNA homeostasis/
protein synthesis
3366 yes
5-methyltryptophan 8 mM tryptophan synthesis metabolism 150990 no
Abietic acid 1 mM lipid synthesis/lipoxygenase lipid biosynthesis 10569 no
Acifluorfen methyl 156.25 ng/ml porphyrin synthesis/
protoporphyrinogen oxidase
metabolism 91642 no
(Aconitine) 200 ug/ml membrane potential/Na+
channels (mammals)
membrane polarization 245005 no
Aflatoxin B1 100 ug/ml DNA damaging agent DNA homeostasis 14403 no
Agelasine D 5 ug/ml membrane potential/Na+/
K+-ATPase (mammals)
membrane polarization 46231918 no
Alamethicin/U-22324 60 uM membrane integrity/forms a
voltage-depended ion channel
membrane polarization 16132042 no
Alexidine dihydrochloride 125 ug/ml antimicrobial/mitochondria mitochondria 102678 yes
Allantoin 100 ug/ml nitrogen-rich compound metabolism 204 topical
Alternariol 2.5 ug/ml cholinesterase inhibitor/sodium
channel activator and DNA
supercoiling/topoisomerase I
broad spectrum 5359485 no
Alumininum sulfate 1.5625 mM unknown unknown 24850 no
(Amantadine
hydrochloride)
1.25 mM neurotransmitter release/
glutamate receptor
signaling 64150 yes
Amiodarone 60 ug/ml membrane potential/Na+/
K+-ATPase (mammals)
membrane polarization 2157 yes
(Ammonium persulfate) 50 mM reactive oxygen species apoptosis/stress response/
damage response
62648 no
Amphotericin B 1 ug/ml lipid biosynthesis/ergosterol membrane integrity 5280965 yes
Andrastin A 4 ug/ml protein modification/
farnesyltransferase
protein trafficking 6712564 no
Anisomycin 50 uM translation/peptidyl transferase gene expression 253602 no
Antimycin 100 ug/ml respiration/cytochrome B metabolism 14957 no
Apicidin 312.5 ng/ml chromatin regulation/HDACs gene expression 6918328 no
Artemisinin 312.5 mM iron metabolism/hematin
detoxification
metabolism 68827 yes
Ascomycin 3.125 uM signaling/calcineurin signaling 6437370 yes
Azide 62.5 uM respiration/cytochrome
C oxidase
metabolism 33558 no
Barium chloride 16 mM metal homeostasis/diverse broad spectrum/unknown 25204 no
Bafilomycin 4 ug/ml autophagy/vacuolar-type
H+-ATPase
protein turnover 6436223 no
Bathocuproine
disulphonic acid (BCS)
3 mM copper acquisition metabolism 16211287 no
(Continued on next page)
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Table 1. Continued
Inhibitor (Activator)
Highest
Screening Conc. Process/Enzyme Category Pubchem ID FDA Approval?
Bathophenanthroline
disulfonate (BPS)
300 uM iron acquistion/Fet3-Ftr1 metabolism 65368 no
Benomyl 100 ug/ml cytoskeleton function/tubulin cell structure 28780 no
(Betulinic acid) 64 ug/ml protein degradation/proteasome protein turnover 64971 no
Bifonazole 50 ug/ml lipid biosynthesis/HMG-CoA
and ergosterol biosynthesis
membrane integrity 2378 no
Brefeldin A 40 ug/ml ER-Golgi Transport/ARF GEF secretion 5287620 no
Calcium chloride 16 mM metal homeostasis/diverse broad spectrum 5284359 no
Caffeine 2.5 mM DNA damage checkpoint/ATM DNA homeostasis 2519 no
Calcium ionophore
A23187
2.5 ug/ml membrane integrity/peptide that
acts as ionophore
membrane integrity 40486 no
Calcofluor white 500 ug/ml cell wall synthesis/chitin and
cellulose
cell wall 6108780 no
Camptothecin 500 ug/ml DNA supercoiling/topoisomerase I DNA homeostasis 24360 analog
Castanospermine 2.4 mM protein modification/glycosidation protein modification 54445 derivative
Cadmium chloride 1 mM metal homeostasis/diverse broad spectrum/unknown 24947 no
Cerulenin 312.5 ng/ml fatty acid synthesis/beta-
ketoacyl-acyl carrier protein
synthase
lipid biosynthesis 5282054 no
Cesium chloride 128 mM metal homeostasis/diverse broad spectrum/unknown 24293 no
Chlorpromazine
hydrochloride
1.5625 uM phenothiazine antipsychotic
drug (mammals)/dopamine,
seratonin, and other
neuroreceptors
signaling 6240 yes
Chromium (III) chloride 8 mM metal homeostasis/diverse broad spectrum 16211596 no
Ciclopirox olamine 750 ng/ml iron acquisition and other metabolism 38911 yes
Cisplatin 100 ug/ml DNA synthesis DNA homeostasis 157432 yes
Climbazole 0.03125% lipid biosynthesis/ergosterol
biosynthesis and respiration/
cytochrome P450
broad spectrum 37907 topical
Clotrimazole 500 nM lipid biosynthesis/ergosterol
biosynthesis
membrane integrity 2812 yes
Colistin 1 mg/ml membrane integrity membrane integrity 5311054 yes
Congo red 0.0625% cell wall synthesis/chitin,
cellulose, and glucan
cell wall 11313 no
Coniine 0.15625% neurosignaling (mammals)/
nicotinic receptor
signaling 441072 no
(Crystal violet) 0.0012500% oxidative stress inducer stress response 11057 topical
CuCl2 8 mM copper homeostasis/diverse metabolism 24014 no
Cycloheximide 1.875 ug/ml translation/ribosome gene expression 6197 no
Cyclopiazonic acid 15.625 uM ion transport and cell polarization
(mammals)/Ca2+- ATPase
metabolism 54682463 no
Cyclosporin 75 ug/ml signaling/calcineurin signaling 5284373 yes
Cyproconazole 1.5625 ug/ml lipid biosynthesis/ergosterol
biosynthesis
membrane integrity 86132 no
Cyprodinil 10 ug/ml methionine biosynthesis metabolism 86367 no
Daphnetin 100 uM signaling/PKA, PKC, EGR
receptor, others
signaling 5280569 no
Desipramine
hydrochloride
250 uM neurosignaling (mammals)/
norepinephrine transporter
signaling 65327 yes
(Continued on next page)
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Table 1. Continued
Inhibitor (Activator)
Highest
Screening Conc. Process/Enzyme Category Pubchem ID FDA Approval?
Dyclonine hydrochloride 3.125 uM lipid biosynthesis/ergosterol
biosynthesis
membrane integrity 68304 yes
Emetine dihydrochloride
hydrate
5 mM translation/ribosome gene expression 3068143 yes
Emodin 62.5 uM signaling/CK2, others signaling 3220 yes
Erlotinib 50 ug/ml signaling (mammals)/EGFR
tyrosine kinase
signaling 176870 yes
FeCl3 32 mM iron acquisition, metal
homeostasis
metabolism 24380 no
Fenoxanil 80 ug/ml melanin biosynthesis metabolism 11262655 no
Fenpropimorph 2.5 ug/ml sterol synthesis lipid biosynthesis 93365 no
FK506 312.5 ng/ml signaling/calcineurin signaling 445643 yes
Fluconazole 10 ug/ml lipid biosynthesis/ergosterol
biosynthesis
membrane integrity 3365 yes
Fluspirilene 25 uM antipsychotic drug, mechanism
of action unknown
unknown 3396 yes
Gallium (III) nitrate 25 mM metal homeostasis/diverse broad spectrum 57352728 no
Geldanamycin 2 uM protein folding/Hsp90 protein folding 5288382 trials
(H2O2) 6 mM reactive oxygen species apoptosis/ stress
response/damage
response
784 topical
Haloperidol 125 uM phenothiazine antipsychotic drug
(mammals)/dopamine, seratonin,
and other neuroreceptors
signaling 3559 yes
Harmine hydrochloride 1 mM cell differentiation (mammals)/
PPARgamma
signaling 5359389 yes
Hydroxyurea 12.5 mM DNA replication/replication fork
progression
DNA homeostasis 3657 yes
Hygromycin 37.5 ug/ml translation/ribosome gene expression 35766 no
Imazalil 25 ug/ml lipid biosynthesis/ergosterol
synthesis
membrane integrity 37175 no
Iodoacetate 500 uM protein degradation/cysteine
peptidases
protein turnover 5240 no
Itraconazole 1.5625 ug/ml lipid biosynthesis/ergosterol
synthesis
membrane integrity 55283 yes
K252a 10 ug/ml signaling/variety of kinases signaling 127357 trials
Latrunculin 25 uM cytoskeleton function/actin cell structure 445420 no
Lead (II) nitrate 64 mM metal homeostasis/diverse broad spectrum 24924 no
Leptomycin 1.25 ug/ml nucleocytoplasmic transport/
Crm1
gene expression 6917907 no
LiCl 37.5 mM metal homeostasis/diverse broad spectrum/
unknown
433294 no
Lovastatin 37.5 ug/ml sterol synthesis/HMG CoA
reductase
metabolism 53232 yes
LY 294002 375 uM signaling/PI3K signaling 3973 no
Magnesium chloride 150 mM metal homeostasis/diverse broad spectrum 21225507 no
Malachite green 3.125 ug/ml antimicrobial/unknown antimicrobial 11294 no
Manganese sulfate 128 mM metal homeostasis/diverse metabolism 177577 no
Mastoparan 5 uM signaling/G-proteins signaling 5464497 no
(Menadione) 150 uM vitamin K3/reactive oxygen
species
diverse 4055 yes
(Continued on next page)
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Table 1. Continued
Inhibitor (Activator)
Highest
Screening Conc. Process/Enzyme Category Pubchem ID FDA Approval?
Menthol 1 mM voltage-dependent ion channels
(mammals)/sodium channel
signaling 16666 yes
Methotrexate 2.5 uM folate synthesis/DHFR metabolism 126941 yes
Methyl methanesulfonate
(MMS)
0.0165% DNA replication/replication fork
progression
DNA homeostasis 4156 no
Methylbenzethonium
chloride (MBT)
0.25% antimicrobial antimicrobial 5702238 topical
MG132 12.5 uM protein degradation/proteasome protein turnover 462382 no
Miconazole 6.25 ug/ml lipid biosynthesis/ergosterol
synthesis
membrane integrity 4189 yes
Mitomycin C 12 uM DNA damaging agent DNA homeostasis 5746 yes
Myclobutanil 2 ug/ml lipid biosynthesis/ergosterol
synthesis
membrane integrity 6336 no
Mycophenolic acid 2.5 ug/ml GMP synthesis/IMP
dehydrogenase
metabolism 446541 yes
Myriocin 12.5 ug/ml sphingolipid synthesis metabolism 6438394 analog
NA8 unknown unknown no
(NaCl) 37.5 mM osmotic regulation/HOG pathway stress response 5234 yes
(NaNO2) 150 uM reactive nitrogen species stress response 23668193 no
Neomycin sulfate 2.4 mM protein synthesis/ribosome gene expression 8378 yes
Nicotinamide 25 uM chromatin regulation/sirtuins gene expression 936 yes
Nigericin 100 ug/ml membrane integrity/ion gradient membrane polarization 34230 no
Nikkomycin 5 ug/ml chitin synthesis cell wall 72479 trials
NiSO4 1 mM antifungal/diverse antifungal 5284429 no
Nocodazole 30 uM cytoskeleton function/tubulin cell structure 4122 no
Ophiobolin A 62.5 ng/ml signaling/calmodulin signaling 5281387 no
Parthenolide 150 uM immune and inflammatory
response/NF-kB
signaling 6473881 no
Pentamidine isethionate 500 uM antimicrobial/mitochondrial
function
antimicrobial 8813 yes
pH 8.0, 8.5, 9.0 pH homeostasis diverse no
Phenylarsine oxide 2.5 uM broad/XCXXCX protein
phosphatases
broad spectrum 4778 no
Picoxystrobin 6.25 ug/ml quinone outside inhibitor
class/fungal cytochrome bcI
mitochondria 11285653 no
(Plumbagin) 2.8 uM reactive oxygen species stress response 10205 no
PMSF 10 mM vacuolar proteolysis/
proteinase B
signaling 4784 no
Polyoxin B 200 ug/ml chitin synthesis cell wall 3084093 no
Povidone iodine 2% antimicrobial antimicrobial 410087 topical
Prussian blue 75 mM monocation chelator metabolism 16211064 yes
Quinic acid 2 mM antimicrobial antimicrobial 6508 no
Rapamycin 0.125 uM signaling/TOR kinases signaling 5284616 yes
Rubidium chloride 150 mM potassium metabolism/
competitor
metabolism 62683 no
Rifamycin SV
monosodium salt
200 ug/ml RNA synthesis/RNA
polymerase
gene expression 6324616 yes
S10 unknown unknown no
S8 unknown unknown no
(Continued on next page)
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Table 1. Continued
Inhibitor (Activator)
Highest
Screening Conc. Process/Enzyme Category Pubchem ID FDA Approval?
S-aminoethyl-L-cysteine
(thialysine)
10 uM amino acid metabolism/lysine
analog
metabolism 20048 no
SDS 0.0015625% cell membrane integrity membrane integrity 3423265 no
Selumetinib 150 ug/ml signaling/MAPK (ERK) signaling 10127622 trials
Sertraline 15 ug/ml neurosignaling (mammals)/
seratonin reuptake
neurosignaling 68617 yes
Sodium azide 62.5 uM respiration/cytochrome oxidase mitochondria 33557 no
Sodium borate 10 mM antimicrobial/diverse antimicrobial 21749317 no
Sodium hydrosulfite 6.25 mM antimicrobial, counteracts
some antimicrobials
antimicrobial 24489 no
Sodium iodide 75 mM antimicrobial antimicrobial 5238 yes
Sodium metavanadate 10 mM signaling/protein phosphotyrosine
phosphatases
signaling 4148882 no
(Sodium molybdate) 64 mM respiration/oxygen uptake diverse 61424 no
Sodium selenite 4 mM respiration/oxygen uptake diverse 16210997 yes
Sodium sulfite 100 mM ATP synthesis and accumulation/
unknown
metabolism 24437 no
Sodium tungstate 64 mM metal homeostasis/diverse broad spectrum/unknown 150191 no
Sorafenib 100 uM signaling/VEGF tyrosine kinase signaling 216239 yes
Staurosporine 3 uM signaling/PKC1 signaling 5279 yes
(STF-62247) 400 uM autophagy protein turnover 704473 trials
Sulfometuron methyl 100 ug/ml branch chain amino acid
synthesis/acetolactate synthase
metabolism 52997 no
Suloctidil 400 uM Ca2+ homeostasis in blood
vessels (mammals)/putative
Ca2+ channel blocker
vascular system/
metabolism
5354 formerly
Tamoxifen citrate 10 uM estrogen signaling (mammals)/
estrogen receptor, mixed
agonist/antagonist
signaling 2733525 yes
Taurolidine 0.01% antimicrobial/lipopolysaccharide
detection and signaling
host defense 29566 yes
Tautomycin 250 nM signaling/PP2A signaling 3034761 no
Tellurite 0.1% sulfate assimilation metabolism 115037 no
Terbinafine 75 uM sterol synthesis/squalene
epoxidase
metabolism 1549008 yes
Thiabendazole 200 ug/ml respiration/NADH oxidase mitochondria 5430 yes
Thonzonium bromide 25 uM antimicrobial, pH homeostasis/
V-ATPase
broad spectrum 11102 yes
Tomatine 5 ug/ml glycoalkaloid antifungal of
unknown mechanism/ergosterol
biosynthesis
antifungal/membrane
integrity
28523 no
Trichostatin A 100 uM chromatin regulation/HDACs gene expression 444732 no
Trifluoperazine 200 uM signaling/calmodulin signaling 5566 yes
Trimethoprim 1.6 mg/ml folate synthesis/DHFR metabolism 5578 yes
Tunicamycin 2.5 ug/ml glycosylation/Alg7 secretion 11104835 no
Usnic acid 25 ug/ml antimicrobial antimicrobial 6433557 trials
Valinomycin 20 uM membrane integrity/potassium
exclusion
membrane polarization 5649 no
Verrucarin 5 uM protein biosynthesis/polysome protein turnover 6437060 no
ZnCl2 4 mM metal homeostasis/diverse diverse 5727 no
A list of compounds used in this study, their targets, and the screening concentration.
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deletions with the greatest number of phenotypes are
cnag_07622D (encoding the COP9 signalosome subunit 1) and
cnag_05748D (encoding a Nto1 subunit of the NuA3 histone ace-
tyltransferase). Compounds that elicit the greatest number of
responsive gene deletions (Figure 1F) are the heavy metal salt
sodium tungstate and the trichothecene protein synthesis inhib-
itor verrucarin (Table S5), presumably reflecting the pleiotropic
impact of these molecules on cells.
Gene Ontology Analysis Reveals Processes Associated
with Drug Sensitivity
Drug influx and efflux is thought to be a major general determi-
nant of microbial drug susceptibility (Ferna´ndez and Hancock,
2012), but we also sought functions involved in drug sensitivity.
We investigated this question in an unbiased fashion by
analyzing chemogenomic profiles using Gene Ontology (GO), a
gene annotation approach useful for comparative analyses. We
first identified annotated orthologs of C. neoformans genes rep-
resented in the deletion library and associated GO terms with
these orthologs. We then determined whether the sensitive
gene knockouts that respond to each small molecule are en-
riched for association with particular GO terms relative to a ran-
domized control set (Figure 2, Table S6). We observed that pro-
tein transport-related terms are highly enriched, as are
processes related to ubiquitin modification/proteolysis and
vesicle-mediated transport. These terms are associated with
nine and five compounds, respectively, suggesting that intracel-
lular transport and ubiquitin-mediated protein turnover may play
important general roles in drug sensitivity.
Comparison with S. cerevisiae Chemogenomic Profiling
Data Sets
Chemogenomic profiling has been performed extensively in
S. cerevisiae, allowing us to ask whether genetic responses to
compounds were conserved. We performed a three-way com-
parison with two large-scale studies (Hillenmeyer et al., 2008;
Parsons et al., 2006) (Figure 3A). Our data set has 46 compounds
in common with Parsons et al. (2006) and 29 with Hillenmeyer
et al. (2008); the two S. cerevisiae data sets had 15 compounds
in common. First we identified genes whose knockouts exhibited
a significant (Z % 2.5 or R +2.5) score (‘‘responding’’) when
treated with a small molecule used in more than one data set,
then identified which of those genes had orthologs in both
S. cerevisiae and C. neoformans. We then calculated how
many orthologs responded in both data sets. To adjust for a
greater starting number of common genes when comparing
the S. cerevisiae data sets to each other and control for func-
tional biases, we limited this comparison to genes that also
have orthologs in the C. neoformans knockout collection. The
blue labels for compounds in Figures 3B–3D indicate statistically
significant similarities (p% 0.05) in drug responses. Nearly all of
the compounds in common between the two S. cerevisiae
studies display statistically significant overlap in the genes that
produced sensitivity to a given compound, despite the very
different experimental platforms that were used to assess drug
sensitivity/resistance (13/15 cases; Figure 3B). In striking
contrast, few compounds show significantly conserved genetic
responses when comparing either S. cerevisiae data set withCtheC. neoformans data. For the twoC. neoformans-S. cerevisiae
comparisons, only two of 46 compounds (Figure 3C) and one
of 29 compounds (Figure 3D) show conserved responses,
respectively.
The responses to azole compounds exhibit limited response
conservation between species. Comparing our data set with
Parsons et al., the responses to fluconazole (FLC) and clotrima-
zole, the azoles in both data sets, do not show significant overlap
(Figure 3C). Likewise, between our data set and Hillenmeyer
et al. (2008), no gene orthologs respond to miconazole and clo-
trimazole in both data sets (Figure 3D). In contrast, between the
two S. cerevisiae data sets, the only shared azole, clotrimazole,
shows a significantly similar response (Figure 3B). We compared
published work that examined the transcriptome responses of
S. cerevisiae (Kuo et al., 2010) and C. neoformans (Florio et al.,
2011) to FLC. We found that, while there was significant overlap
in orthologous genes impacted in the two species, (p = 1.6 3
103), there were also considerable differences: 67% of the
genes with an altered response in C. neoformans whose ortho-
logs in S. cerevisiae did not exhibit significant change, (Table
S7) (Kuo et al., 2010).
Using Chemical-Genetic Signatures to Identify Capsule
Biosynthesis Mutants
Studies in S. cerevisiae have shown that that the phenotypic sig-
natures of gene deletions for genes that act in the same process
or protein complex tend to be similar (Collins et al., 2007; Cos-
tanzo et al., 2010; Nichols et al., 2011; Parsons et al., 2004; Par-
sons et al., 2006). We reasoned that this property of could be
used in a pathogen to identify candidates for new genes involved
in virulence by simply testing gene deletions that displayed
phenotypic profiles similar to those corresponding to known
virulence factors.
C. neoformans harbors an inducible polysaccharide capsule
that is unusual among fungi (Del Poeta, 2004; Doering, 2009;
Haynes et al., 2011; Kumar et al., 2011; O’Meara and Alspaugh,
2012; O’Meara et al., 2010; Vecchiarelli et al., 2013). The
principal polysaccharide component, glucuronylxylomannan
(GXM), consists of a repeating glycan unit that has a-1,3-linked
mannose backbone with side chains of b-linked glucuronic
acid and xylose (Kozel et al., 2003). Capsule production is critical
for virulence and the ability of C. neoformans to evade detection
and destruction by the host immune system (Vecchiarelli et al.,
2013).
To identify candidates for genes involved in capsule formation
and/or attachment, we organized our data set using hierarchical
clustering of growth phenotypes produced by compound expo-
sure.We focused on two clusters, each containing a gene(s) pre-
viously implicated in capsule biosynthesis: PBX1 and CPL1 (Liu
et al., 2008; Liu et al., 2007b) in one cluster (Figure 4A) and
CAP60 (Chang and Kwon-Chung, 1998) in a second cluster (Fig-
ure 4B). The pbx1D/cpl1D cluster contains nine genes and the
cap60D cluster seven. We quantified capsule accumulation after
induction by computing the ratio of the diameter of the cell and
capsule to the diameter of the cell alone (Figures 4C and 4D).
Wild-type cells exhibit high capsule production, pbx1D mutants
display a partial defect (Liu et al., 2007a) and cpl1D and cap60D
mutants are acapsular (Chang and Kwon-Chung, 1998; Liu et al.,ell 159, 1168–1187, November 20, 2014 ª2014 Elsevier Inc. 1175
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Figure 2. Determinants of Compound
Sensitivity
We calculated whether molecules elicited a sig-
nificant response from C. neoformans ORFs that
are enriched for association with specific GO
terms. Terms are listed on the y axis and the
number of compounds whose responding gene
knockouts associated with that GO term are listed
on the x axis. See also Table S6.2008). We found that seven of nine mutants in the pbx1D/cpl1D
cluster exhibit a statistically significant capsule defect, as did
four of the seven mutants in the cap60D cluster. In contrast, pre-
vious work from our laboratory found that approximately 1% of
the original C. neoformans library shows a gross defect in
capsule production (Liu et al., 2008).
Previous work showed that pbx1D mutants produce polysac-
charide capsule whose attachment to the cell wall is sensitive to
sonication, a finding that we confirmed (Figures 4C and 4D). We
refer to the cell’s ability to retain GXM on the cell surface as
‘‘capsule maintenance.’’ Knockout mutants in cnag_01058 do
not exhibit a basal capsule defect but lost nearly 40% of their
capsule diameter following sonication. Cells deleted for the
GCN5 gene, like pbx1D cells, show both decreased capsule
levels and sonication-sensitive capsule. None of the mutants
from the cap60D cluster produces a sonication-sensitive pheno-
type, suggesting that the pbx1D/cpl1D and cap60D clusters
organize mutants that have distinct phenotypes. However,
because several mutants do not produce visible capsule, theFigure 1. Chemical-Genetic Profiling of C. neoformans
(A) Heat map of full data set following hierarchical clustering. Compounds are arrayed on the x axis and gene k
(B) Probability density function for pairwise correlation scores between the chemical genetic profiles of differe
different concentrations (purple) screened on different days (different batches).Scores between the chemica
same compounds are significantly higher than those between different compounds (Wilcoxon test, p = 2.7 3
(C) Probability density function for pairwise correlation scores between the chemical genetic profiles of differe
(purple). Pairwise comparisons between azoles exhibit higher correlation scores than nonazole compounds
highest pairwise comparisons scores are listed on the right.
(D) Pearson’s correlation score between two different concentrations of the same compounds. Concentration
(y axis). For compounds with the greatest correlation scores between concentrations, Venn diagrams of sign
same compounds at different concentrations and the small-molecule structure are shown. The orange line i
(E)Histogram showing the number of deletion mutants that have given number of phenotypes. A phenotype is
independently for each small-molecule concentration.
(F) Histogram showing the number of small molecules that have a given number of phenotypes. Phenotypes
condition/concentration
See also Figure S1 and Tables S1, S2, S3, S4, and S5.
Cell 159, 1168–1187, Nosonication test is insufficient to defini-
tively measure capsule maintenance.
We therefore analyzed how much
glucoronoxylomannan (GXM), the major
capsular polysaccharide (Doering, 2009),
is secreted into the growth medium by
blotting with a-GXM antibodies (Fig-
ure S2A). We found that two mutants
that produce little (gcn5D) or no (yap1D)
visible capsule still shed GXM into the
medium, suggesting that they cannot
retain capsule on their cell surface.Indeed, we found that they shed more GXM than pbx1D cells.
Four of nine mutants in the pbx1D/cpl1D cluster exhibit a main-
tenance defect, whereas none of the cap60D cluster mutants do.
We also found that GXM produced by these cells can be taken
up and added to the surface (‘‘donated’’) of an acapsular mutant
using a standard GXM transfer assay (Kozel and Hermerath,
1984; Reese and Doering, 2003). Moreover, apparent capsule-
defective mutants shed GXM (Figures S2B and S2C) and can
donate GXM from conditioned medium (Figure S2C). Mutants
that appear to not secrete GXM (pbx1D, cpl1D, and sgf73D)
can donate it, but only if conditioned medium concentration is
increased 10-fold (Figure S2D). These data are consistent with
a recently published study on the role of Pbx1 in capsule attach-
ment and assembly (Kumar et al., 2014).
Since the capsule is amajor virulence trait ofC. neoformans, we
tested whether knockout mutants that exhibited a capsule defect
displayed a defect in the mammalian host, using a murine inhala-
tion model. We infected mice with a mixture of differentially-
tagged wild-type and mutant cells at a ratio of 1:1. At 10 daysnockouts on the y axis. See also Tables S1 and S2.
nt compounds (gray) and the same compounds at
l-genetic profiles of different concentrations of the
10176). See also Figure S1.
nt compounds (gray) and azole family compounds
(Wilcoxon test, p = 2.8 3 106). Molecules with the
s with similar correlation scores are binned together
ificant genes (Z < 2.5) present in profiles from the
ndicates a hypergeometric p value% 0.05
considered jZj > 2.5 and we identified phenotypes
(jZj > 2.5) were identified for each small-molecule
vember 20, 2014 ª2014 Elsevier Inc. 1177
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Figure 3. Chemical-Genetic Signatures of C. neoformans Genes Differ from Orthologous S. cerevisiae Genes
(A) Flowchart of computation process for comparing data sets.We identifiedC. neoformans andS. cerevisiae orthologous genes that were present in all data sets,
then compared the responses of only those genes in all the data sets. We compared genes whose knockout mutants significantly (jZj > 2.5) responded to
compound that were common in at least two of the data sets.
(B) Comparison between Parsons et al. (2006) and Hillenmeyer et al. (2008), comparing the response (jZj > 2.5) of genes that have orthologs present in the
C. neoformans data set. Compounds whose profiles exhibit significant overlaps (p < 0.05) are labeled in blue.
(C) Comparison between our data set and Parsons et al. (2006) Compounds whose profiles exhibit significant overlaps (p < 0.05) are labeled in blue.
(D) Comparison between our data set and Hillenmeyer et al. (2008) Compounds whose profiles exhibit significant overlaps (p < 0.05) are labeled in blue.
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postinfection (dpi), we sacrificed animals, harvested and homog-
enized lung tissue, then plated on the appropriate selectivemedia
for colony forming units (CFUs). All but one of the pbx1D/cpl1D
cluster members were significantly underrepresented relative to
wild-type; the exception was the cnag_01058D mutant, which is
defective in capsule maintenance but not capsule biosynthesis
(Figures 4C and S2A). yap1D cells, which appear acapsular but
secrete GXM, displayed a major defect in fitness in the host (Fig-
ure 4E). Threeof fourcap60Dclustermutants alsodisplay adefect
in accumulation of CFUs in host lungs (Figure 4E).
Chemogenomics Identifies the Cell Cycle as a Target
of the Antifungal Small Molecule S8
We included a number of drug-like antifungal compounds in our
screen in order to identify their targets (Table 1). Our use of
C. neoformans chemogenomics to assist in the identification of
a target of toremifene is described elsewhere (Butts et al.,
2014). Here we investigate the thiazolidine-2,4-dione derivatives
originally described for their activity against C. albicans biofilms
(Kagan et al., 2014).
Our chemogenomic profiling data of the thiazolidine-2,4-dione
derivative S8 revealed a striking outlier: a knockout mutant in the
gene coding for a C. neoformans ortholog of the conserved cell-
cycle kinase Wee1, is relatively resistant (Figure 5A). We
observed resistance at multiple concentrations of S8 (Table
S2). The related compound NA8, which contains a replacement
of a sulfur atomwith a carbon atom on the thiazolidinedione moi-
ety (Figure 5B), does not elicit the same resistance (Figure S3A).
The wee1D mutant is also resistant to S10 (Figure S3B), which
harbors a C10 alkyl chain instead of C8 but is otherwise identical
to S8 (Figure S3C).
Wee1 regulates the G2/M cell-cycle checkpoint through inhib-
itory phosphorylation of Cdk1, which in turn is required for cells
to traverse the checkpoint. The essential phosphatase Cdc25
activates Cdk1 by removing the inhibitory phosphorylation
added by Wee1 (Morgan, 2007) (Figure 5C). Because the
wee1D is relatively resistant to S8, we hypothesized that S8 tar-
geted a protein that acts through Wee1 to regulate Cdk1. One
such target could be Cdc25.
We reasoned that if theWee1/Cdc25-regulated step of the cell
cycle were an important target of S8 in vivo, wild-type
C. neoformans cells treated with S8 would arrest at G2/M. To
test this prediction, we treated exponential cultures with S8,
S10, or NA8 and examined the impact on the cell cycle. We har-
vested and fixed representative samples every 30 min, then
analyzed DNA content by flow cytometry. Control cultures
treated with DMSO (carrier) (Figure 5D) or the control compound
NA8 (Figure 5E) stayed asynchronous for the entire 3.5 hr of the
time course. Strikingly, S8-treated (Figure 5F) cells accumulated
with 2C DNA content, which indicates G2/M arrest in
C. neoformans, a haploid yeast (Whelan and Kwon-Chung,
1986). At later time points, cells synthesize DNA but do not
complete mitosis and cytokinesis. This is consistent with obser-
vations in S. pombe that partial inhibition of Cdk1 permits re-
replication of DNA (Broek et al., 1991).
Because inhibition of Cdc25 would provide a parsimonious
explanation for the genetic and biological properties of S8, we
tested whether S8 inhibits C. neoformans Cdc25 in vitro. We ex-Cpressed and purified the catalytic domain of a C. neoformans or-
tholog (CNAG_07942) in E. coli (Figure S3D) and then performed
in vitro phosphatase assays using 3-O-methyl fluorescein phos-
phate (OMFP) as a substrate (Figures 5Gand5H) (Hill et al., 1968).
We observed that S8 inhibits Cdc25 activity (Ki 140 mM, Fig-
ure5E), asdobothS10 (FigureS3E)andNSC663284 (Ki250mM,
Figure S3F), a commercially available inhibitor of mammalian
Cdc25 (Pu et al., 2002). The control compound NA8 does not
inhibit C. neoformans Cdc25 in vitro (Figure S3G). For S8, the
in vitro inhibition constant is roughly comparable to the liquid
MIC value against C. neoformans, which we measured to be
60 mM in YNB. S10 has a higher Ki (Ki310 mM) but similar to
the MIC value (55 mM) measured in YNB agar compared to S8.
O2M: A Genetic Biomarker Algorithm to Predict
Compound Synergies
Drug resistance is a major clinical challenge in the treatment of
both bacterial and fungal infections (Anderson, 2005; Cantas
et al., 2013). An effective therapeutic strategy is to treat patients
with drugs that act synergistically, enhancing each other’s effec-
tiveness beyond that produced by the sum of each drug’s indi-
vidual impact (Kalan andWright, 2011). This approach is thought
to decrease acquisition drug resistance, increase the available
drug repertoire (Kalan and Wright, 2011) and ameliorate toxic-
ities (Kathiravan et al., 2012; Leha´r et al., 2009).
We hypothesized that we could use the chemogenomic infor-
mation from our screens of drugs known to act synergistically,
such as FLC and fenpropimorph (Jansen et al., 2009), to identify
new synergistic interactions (Figure 6A). When we compared the
identity of genes whose knockouts ‘‘responded’’ to each individ-
ual small molecule in a known synergistic pair (jZjR 2.5, Tables
S3 and S4), we found that this ‘‘responsive’’ gene set was signif-
icantly enriched over the expected value (Fisher’s exact test, p%
6 3 105) (Figure 6A, top). This observation is consistent with a
previous report that the chemical-genetic response to each
drug in a synergistic pair is enriched for overlapping genes (Jan-
sen et al., 2009).
This overlap in responsive gene sets led us to consider the
possibility that overlapping responsive genes from known syner-
gistic compound pairs could be used as biomarkers to predict
new synergistic combinations. Our method involves first identi-
fying the overlaps in responsive gene sets for all compounds
that had been reported in the literature to synergize with a small
molecule of interest (‘‘compound X’’), selecting those genes
common to all of those sets (Figure 6A, middle, the overlaps of
overlaps). We refer to these genes as ‘‘synergy biomarker
genes.’’ Critically, we next hypothesized that any compound
that contains one or more of these synergy biomarker genes in
its responsive gene set would be synergistic with compound X.
Because our method used the overlaps of response gene over-
laps between compounds known to be synergistic, we refer to it
as the ‘‘overlap-squared method’’ or ‘‘O2M.’’
We then tested O2M using two drugs for which substantial
literature synergy information was available: FLC and geldana-
mycin (GdA). FLC is an approved antifungal drug. GdA is an in-
hibitor of Hsp90, a chaperone protein with many physical and
genetic interactions (Taipale et al., 2010). We performed our
analysis on fenpropimorph and sertraline, which are known toell 159, 1168–1187, November 20, 2014 ª2014 Elsevier Inc. 1179
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Figure 4. Chemical-Genetic Profiling Identifies Genes Involved in Capsule Biosynthesis
(A) Cluster containing the chemical signatures of the pbx1D and cpl1D mutants.
(B) Cluster containing the chemical signatures of the cap60D mutants.
(legend continued on next page)
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act synergistically with FLC (Jansen et al., 2009; Zhai et al.,
2012), and cyclosporine and rapamycin, which are known to
act synergistically with GdA (Francis et al., 2006; Kumar et al.,
2005). Using this prior knowledge and our data, we identified
synergy biomarker genes for FLC (CNAG_00573, CNAG_
03664, and CNAG_03917) and GdA (CNAG_01172, CNAG_
03829, and CNAG_01862). We generated a list of compounds
from our chemical-genetics data set that contain one or more
of these genes in their responsive genes set.
We then used a standard ‘‘checkerboard’’ assay to experimen-
tally determine fractional inhibitory concentration index (FICI),
and we adopted the standard that an FICI value below 0.5 is syn-
ergistic (Meletiadis et al., 2010).Wedetermined FICIs for FLCand
GdAwith three sets of compounds: (1) the compounds predicted
fromsynergybiomarker genes, (2) thepredicted synergistic com-
pounds for the other drug (e.g., we tested compounds predicted
to be synergistic with GdA for synergy with FLC), and (3) a
randomly generated subset of the compounds not predicted to
act synergistically with either FLC or GdA. The second and third
groups are as controls for compounds that are generally syner-
gistic and to determine the background frequency of synergistic
interactions within a set of compounds.
Respective experimental FICI values for FLC and GdA are
shown in Figures 6B and 6C (yellow bars: synergy; blue bars ad-
ditive or worse interactions). The labels for compounds we pre-
dicted to be synergistic are colored purple, positive controls
(published synergistic compound pairs) are colored green, and
predicted negative control compounds are colored blue (Fig-
ure 6). We observed that only10%of the negative control com-
pounds act synergistically with either FLC or GdA. In striking
contrast, we found 80% and 60% of the compounds
selected byO2Mare synergistic with FLC andGdA, respectively.
Thus, for two unrelated compounds, O2M is highly successful at
predicting synergistic interactions and performs vastly better
than the brute force trial-and-error approach (Figures 6D and
6E) (p < 0.0008, Fisher’s exact test).
DISCUSSION
We applied chemogenomic profiling to the major fungal driver of
AIDS-related death, the encapsulated yeast C. neoformans, to
produce a chemical-genetic atlas of this important pathogen.
Beyond identifying new virulence factors and compound mode
of action, we describe a conceptually general approach to iden-
tifying drug synergies that combines prior knowledge and che-
mogenomic profiles.
A Chemical-Genetic Atlas for C. neoformans
Wemaximized the quality of the atlas in several ways. To capture
concentration-dependent impacts of compounds, we obtained
the MIC for each compound and examined the genetic re-(C) Images of individual cells grown in 10%Sabouraud’s broth to induce capsule.
phenotype. Scale bar, 5 mm.
(D) Quantification of capsule sizes from all mutants in pbx1D/cpl1D (purple labe
strain, the error bars represents the standard deviation, and p values were calcu
(E) Colony counts from colony forming units (cfu) extracted frommouse lungs follo
bars represent the standard deviation and p values were calculated using Stude
Csponses at multiple concentrations below MIC. In addition, we
performed a large number of control screens and incorporated
batch information for systematic correction. Overall benchmarks
of data quality (Figure 1) together with nearest neighbor and
Gene Ontology analysis (Figure 2) support the existence of sub-
stantial chemical-genetic signal in the data. Even genes with
orthologs in both S. cerevisiae and C. neoformans show consid-
erable differences in responses (Figure 3). While this may not be
surprising given the large phylogenetic distance between these
fungi, it shows that understanding the chemical responses of
pathogens requires pathogen-focused studies, even when
considering conserved genes and processes. For example, we
observed differences in the responses to azole drugs between
S. cerevisiae and C. neoformans (Figure 3). Since azoles are
heavily used clinically, differences in responses between species
are of significant interest.
Insights Gained from Initial Use of the C. neoformans
Chemical-Genetic Atlas
Identification of Mutants that Impact Capsule Formation
and Mammalian Infection
Our studies on capsule biosynthesis genes focused two different
clusters that contained genes that we and others have shown to
be required for capsule formation, the pbx1/cpl1D cluster and
the cap60D cluster. As anticipated frommodel organism studies
(Collins et al., 2007; Costanzo et al., 2010; Nichols et al., 2011;
Parsons et al., 2004; Parsons et al., 2006), these clusters were
indeed enriched for genes whose mutants are defective in
capsule biosynthesis and mammalian pathogenesis. The genes
represented by the two clusters differed functionally in that
genes in the pbx1/cpl1D cluster but not the cap60D cluster are
required for association of capsule polysaccharide with the cell
surface (Figures 4 and S2). A recent study on Pbx1 and its ortho-
log, Pbx2, proposes that the two proteins act redundantly in
capsule assembly (Kumar et al., 2014). pbx1D and pbx2D cells
shed lower amounts of GXM into the culture medium but that
the GXM functions in a capsule transfer assay. Electron micro-
scopy studies indicate that these mutants exhibit defects in the
cell wall. Our data are fully consistent with these data. Other
genes from the pbx1D/cpl1D cluster likely play a role in these
processes. Some, like GCN5 and SGF73, which encode ortho-
logs of the yeast SAGA histone acetylase/deubiquitylase com-
plex, are clearly regulatory, while others could act more directly.
While detailed validation and investigation of these many candi-
dates (including gene deletion reconstruction studies) will be
required to obtain mechanistic insight into capsule biology, their
enrichment suggests value of this Cryptococcal chemogenomic
resource in identifying mutants defective in virulence.
Compound Target Identification
Chemogenomic profiling has proven useful in identifying targets
of uncharacterized compounds (Parsons et al., 2006), includingRepresentative cells are shown for mutants that exhibit a statistically significant
ls) cluster or cap60D (green labels) cluster. 100 cells were measured for each
lated using Student’s t test.
wing an inhalation infection. Three mice are shown for each datapoint; the error
nt’s t test.
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in the pathogenic fungus C. albicans (Jiang et al., 2008; Xu et al.,
2007; Xu et al., 2009). Chemical-genetic data can be used to
determine the target of compounds within complex mixtures
(Jiang et al., 2008; Xu et al., 2009). Our goal differed: we sought
to identify targets of repurposed compounds, as described else-
where (Butts et al., 2013), or, in the case of S8, a compound iden-
tified as an inhibitor of Candida biofilms (Kagan et al., 2014). The
identification of the Wee1 kinase as a sensitivity determinant for
S8, the cell-cycle arrest produced by S8, and the ability of the
compound to inhibit CnCdc25 in vitro together support the
model that S8 inhibits growth through via the cell cycle at least
in part via inhibition of Cdc25. Whether this explains its impact
on biofilms requires further investigation. As with any compound
target, ultimate proof that Cdc25 is the target of S8 will require
the isolation of resistance alleles of CDC25.
Given the simplicity of the pharmacophore and its Ki for
CnCdc25, it would not be surprising if S8 had additional cellular
targets, as recently described (Feldman et al., 2014). Cdc25 is a
conserved cell-cycle phosphatase and therefore might be
considered a poor drug target a priori but cyclin-dependent ki-
nases are a focus of recent antiparasite therapeutics (Geyer
et al., 2005). It is also notable that the target of azole antifungals,
lanosterol 14-demethylase (Ghannoum and Rice, 1999) is
conserved from yeast to human.
O2M: Predicting Compound Synergies Using Prior
Knowledge and Chemical Profiles
Identifying synergistic drug interactions is of considerable clin-
ical interest, but efficient methods for their identification are
elusive. Systematic examination of combinations of a small set
of compounds using S. cerevisiae suggests that synergies are
relatively rare and often involve so-called ‘‘promiscuous’’ syner-
gizers, compounds that are synergistic with multiple partners
(Cokol et al., 2011). Chemogenomic studies have shown that
drugs known to be synergistic tend to have overlapping ‘‘re-
sponding’’ gene sets (Jansen et al., 2009). We expanded on
this concept to develop a highly parallel method, O2M, for effi-
ciently predicting synergistic drug interactions. Our work utilizes
prior knowledge of drug synergies to identify a discrete set of
predictive biomarker genes for a given compound. We experi-
mentally demonstrated the utility of O2M for two compounds,
FLC and geldanamycin. Our method identified dozens of syner-
gistic interactions and discovered a small number of biomarkers
that could serve as readouts for further screens for synergistic
drugs. The method appears to not simply select promiscuous
synergiziers: five of six drugs previously classified as promiscu-Figure 5. C. neoformans Cdc25 Is a Target of S8 In Vivo and In Vitro
(A) Chemical-genetic data of the growth scores of each knockout mutant grown
mutant strain that showed the greatest sensitivity to S8 is cnag_04462D.
(B) Structures of S8, NA8, and NSC 663284. The structure of S10 is shown in Fig
(C) G2/M regulation (Morgan, 2007).
(D) DNA content of asynchronousC. neoformans culture split into aliquots for treat
Data for DMSO-treated culture is shown.
(E) DNA content from NA8-treated culture from same starting culture as Figure 5
(F) DNA content from S8-treated culture from same starting culture as Figure 5F
(G) Phosphatase activity of purified C. neoformans Cdc25 catalytic domain (CNA
the error bars represent the standard deviation.
(H) Michaelis-Menten kinetics of S8 inhibition of CnCdc25 from in vitro phosphata
value (0.94).
Cous synergizers (Cokol et al., 2011) were tested in our studies but
most were not predicted to be synergistic by O2M. One of the
promiscuous compounds was a positive control (fenpropimorph
with FLC) and another (dyclonine) was predicted synergistic with
FLC but was not and was predicted not synergistic with GdA but
was. We anticipate that O2M could be used to identify synergis-
tic compound interactions in published E. coli and C. albicans
chemical-genetics data sets (Jiang et al., 2008; Nichols et al.,
2011; Xu et al., 2007; Xu et al., 2009).
EXPERIMENTAL PROCEDURES
Determination of MICs
We determined MIC on solid growth medium for each compound used in
screening (Table 1).
Colony Array-Based Chemogenomic Profiling
C. neoformans knockouts were inoculated from frozen 384-well plates to
YNB + 2% glucose. Plates were grown 24 hr at 30C, then used to inoculate
screening plates containing compounds of interest.
Data Analysis
Data were analyzed as previously described (Baryshnikova et al., 2010) with
the a few exceptions.
C. neoformans Ortholog Identification and GO Term Mapping
Mapping from S. cerevisiae Uniprot Proteins to C. neoformans Uniprot
Proteins was done using One-to-one mappings in MetaPhOrs (http://
metaphors.phylomedb.org/). C. neoformans ORFs were compared to a data-
base of S. cerevisiae Uniprot Proteins using blastp (Altschul et al., 1997) with a
E-score cutoff of 1030. Corresponding yeast GO annotations were mapped
onto the C. neoformans ORFs.
Comparison of Transcriptional Response to FLC
Compared transcriptional responses between S. cerevisiae (Kuo et al., 2010)
and C. neoformans (Florio et al., 2011).
Capsule Induction Assay
Samples were grown overnight at 30C in 100% Sabouraud’s broth, then
diluted 1:100 into 10% Sabouraud’s broth buffered with 50 mM HEPES pH
7.3 and grown for 3 days at 37C. India ink was added at 3:1 ratio and samples
imaged on a Zeiss Axiovert microscope.
Capsule Transfer Assay
Performed as in (Reese and Doering, 2003), with minor modifications.
GXM Immunoblot Assay
Conditioned medium was made from donor GXM donor strains as described
above.on S8 (y axis). The mutant that exhibited the greatest resistance is wee1D. The
ure S3C.
ment with compounds of interest, with samples harvested at appropriate times.
F.
.
G_01572, aa442-662). Average of three independent replicates are shown and
se activity. A noncompetitive model of enzyme inhibition produced the best R2
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MBT
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(legend on next page)
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Mouse Infection Assay
Mouse lung infections were performed as previously described (Chun et al.,
2011).
Cdc25 Protein Purification
We identified the C. neoformans ortholog of Cdc25, CNAG_01572, by best
reciprocal BLAST (Altschul et al., 1997) hit with the human Cdc25A,
Cdc25B, and Cdc25C protein isoforms. We then inserted the exonic
sequence of the catalytic domain into a 63-His tag expression vector for
purification.
Cdc25 Phosphatase Assay
Cdc25 phosphatase activity was analyzed in activity buffer (50mMTris pH 8.3,
5% glycerol, 0.8 mM dithiolthreitol, and 1% PVA).
Cdc25 Inhibitor Treatment and FACS Analysis
Wild-type C. neoformans was grown overnight in 13 YNB at 30C with
rotation. Cultures were diluted to OD600 0.2 into 150 ml 13 YNB, then
incubated 3 hr at 30C. Samples were then split and NA8, S8, and S10
added to 60 mM. Equivalent volume of DMSO was added to the control
culture.
Fractional Inhibitory Concentration Index Assay for Synergy
We determined FICI using a standard checkerboard assay (Hsieh et al., 1993),
calculating FICI as described using a 50% growth inhibition cutoff for MICs for
individual compounds (Hsieh et al., 1993; Meletiadis et al., 2010), then using a
standard cutoff of FICI < 0.5 to define synergy.
See Extended Experimental Procedures for additional details.
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